Imfinzi + nya immunoterapier förbättrade kliniska utfall vid icke resekterbar NSCLC i stadium III
Imfinzi combined with novel immunotherapies improved clinical outcomes for patients with unresectable, Stage III non-small cell lung cancer
COAST Phase II trial showed oleclumab or monalizumab in combination with Imfinzi significantly delayed disease progression and increased objective response rate.
